Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1043
Embargo will expire:
18-Jul-2018 2:00 PM EDT
Released to reporters:
17-Jul-2018 9:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 18-Jul-2018 2:00 PM EDT

BlueDesig_group.jpg

Article ID: 697382

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Recognized for Quality in Value Based Cancer Care

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have been recognized with a Blue Distinction® Centers for Cancer Care designation as part of the Blue Distinction Specialty Care program.

Released:
12-Jul-2018 3:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
samir_hanash.jpg
  • Embargo expired:
    12-Jul-2018 11:00 AM EDT

Article ID: 697285

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

University of Texas M. D. Anderson Cancer Center

A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment to improve eligibility criteria for lung cancer screening with low-dose computed tomography,” said study co-senior author Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center.

Released:
11-Jul-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
main.jpg

Article ID: 697335

Deadly Form of Advanced Prostate Cancer Is Common, Calls for Distinct Treatment

UCSF Helen Diller Family Comprehensive Cancer Center

A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.

Released:
12-Jul-2018 10:55 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 697277

Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian Cancers

Ludwig Cancer Research

Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.

Released:
11-Jul-2018 12:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 697306

Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian Cancers

Cancer Research Institute and the Ludwig Cancer Research

A clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers has been initiated.

Released:
11-Jul-2018 10:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 697252

Tip Sheet: Immunotherapy for Deadly Skin Cancer; More Money but No Better Outcome; Yoga and Music for Breast Cancer Therapy; Molecular Discoveries; Caregivers

Fred Hutchinson Cancer Research Center

This month's tip sheet from Fred Hutch includes story ideas about immunotherapy for a deadly type of skin cancer, cancer care that costs twice as much but yields no better outcome, yoga and music therapies for breast cancer and more. To pursue any of these story ideas, please contact the individual listed for each.

Released:
10-Jul-2018 3:25 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Tejas.Patil.jpg

Article ID: 697230

Brain Metastases Common and Difficult to Treat in ROS1 Lung Cancer

University of Colorado Cancer Center

Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression.

Released:
10-Jul-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
KinneyAnita_0718DV.jpg

Article ID: 697223

Improving Public Health by Understanding Cancer Risk

Rutgers Cancer Institute of New Jersey

Aiming to reduce cancer risk, improve the understanding of cancer outcomes, and promote cancer health equity in the most vulnerable populations at the community level, the Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey have recruited Anita Y. Kinney, PhD, to two new leadership roles.

Released:
10-Jul-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 697154

Ludwig-Developed Candidate Cancer Drug May Be Effective Against Broader Class of Brain Cancers

Ludwig Cancer Research

A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor (EGFR), a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme (GBM).

Released:
9-Jul-2018 4:15 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

110 of 1043





Chat now!